Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 31, 2015 8:12 AM ET


Company Overview of Jounce Therapeutics, Inc.

Company Overview

Jounce Therapeutics, Inc. engages in the discovery and development of a pipeline of cancer immunotherapy treatments for a range of cancers. Its immunotherapies are designed to harness the patient's immune system to seek out and attack cancerous cells and tumors. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

1030 Massachusetts Avenue

Cambridge, MA 02138

United States

Founded in 2012





Key Executives for Jounce Therapeutics, Inc.

Chief Executive Officer
Age: 55
Compensation as of Fiscal Year 2014.

Jounce Therapeutics, Inc. Key Developments

Jounce Therapeutics, Inc. Appoints Deborah Law, D. Phil., to the Position of Chief Scientific Officer

Jounce Therapeutics, Inc. announced the appointment of Deborah Law, D. Phil., to the position of chief scientific officer. Dr. Law brings to Jounce nearly two decades of experience in biologics drug discovery and development, particularly in the fields of oncology and immunology. Dr. Law joins Jounce from Merck, where she most recently served as vice president of Therapy Area Biology for Immunology, Oncology and Immunomodulators. In this role, she was responsible for bringing cancer immunotherapy compounds from discovery to the clinic. Prior to Merck, Dr. Law served as the chief scientific officer for Ablynx n.v. and held various research positions in biotechnology companies including PDL Biopharma, EOS Biotechnology and Cor Therapeutics.

Jounce Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 10:00 AM

Jounce Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 10:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Richard Murray, Chief Executive Officer.

Jounce Therapeutics, Inc. Announces Executive Changes

Jounce Therapeutics, Inc. announced the appointment of Richard Murray, Ph.D., to chief executive officer. Dr. Murray brings to Jounce more than two decades of experience building biologics R&D capabilities and moving exciting science through development for both startup biotechnology and large pharmaceutical companies. Dr. Murray succeeds interim CEO Cary Pfeffer, M.D., who will assume the position of chairman of Jounce's board of directors. Dr. Murray joins Jounce from Merck, where he most recently served as senior vice president, biologics & vaccines research, and was a member of the Merck Research Laboratories (MRL) leadership team.

Similar Private Companies By Industry

Company Name Region
Carthan Pharma United States
Caribbean Pharmalogic Inc. United States
Sabinsa Corporation United States
Zacharon Pharmaceuticals, Inc. United States
Pernix Sleep, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Jounce Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at